Ebola Outbreak in DRC Raises Urgent Need for New Vaccines and Treatments

The Democratic Republic of Congo is facing its third-largest Ebola outbreak, caused by the Bundibugyo strain, which has previously led to significant fatalities. Despite the existence of a vaccine for the more common Zaire strain, no approved vaccines or treatments are currently available for Bundibugyo. Scientists are exploring the potential use of the Zaire-targeted vaccine, Ervebo, but its effectiveness and safety against Bundibugyo remain uncertain. New experimental vaccines are being prioritized, with promising results in animal trials, but human testing materials may take six to nine months to develop. This situation underscores the urgent need for rapid vaccine development in response to emerging infectious diseases.

Key Details: • The current outbreak is the 17th Ebola outbreak in DRC since 1976. • Ervebo vaccine has not been proven effective against Bundibugyo strain. • New experimental vaccines are being prioritized, with testing expected to take 6-9 months. • Merck has supplied over 500,000 doses of Ervebo to a global stockpile. • Potential collaborations for vaccine development are being explored by Merck and IAVI.